CellFE and Syenex Collaborate to Advance Cell Engineering with Hybrid Gene Editing Workflow | PR Newswire [Video]

, /PRNewswire/ — CellFE^®, a leader in non-viral gene editing technology, and Syenex, a pioneer in enveloped delivery vectors, have announced an innovative collaboration to create a hybrid workflow that seamlessly integrates non-viral and viral approaches to cell therapy engineering. This next-generation process aims to enable streamlined workflows of complex edited cells for biotech and pharmaceutical applications. 

CellFE® and Syenex announce collaboration on hybrid gene editing workflow ahead of the JP Morgan Healthcare Conference.

The collaboration application note will be officially unveiled the week of the highly anticipated J.P. Morgan Healthcare Conference in San Francisco this January, a premier event that brings together industry leaders, investors, and innovators from around the world.

“The market has been anticipating a solution that seamlessly integrates non-viral knockout with viral knockin capabilities into a streamlined workflow—one that preserves cell viability and functionality without compromise.” said Dr. Alla Zamarayeva, CEO of CellFE. “By collaborating with Syenex, we are directly addressing …